Entries by raincastle

Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

November 13, 2019 — Quizartinib, a once-daily, oral, highly potent and selective FLT3 inhibitor, demonstrated a significant improvement in survival vs SC in FLT3-ITD-positive R/R AML in the global, randomized, phase 3 QuANTUM-R study (Cortes et al. Lancet Oncol, 2019; NCT02039726). Patients with R/R FLT3-ITD-positive AML were randomized 2:1 to receive single agent quizartinib or […]

Unlocking the Value of Complex Biomarker Data

November 8, 2019 — This article explores biomarker data trends and challenges, and shares how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can reduce time and cost.

Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology

March 6, 2019 — Bethesda, MD — Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in […]

Using Selection Biomarkers to Drive Clinical Trial Success

March 4, 2019 — Since the turn of the century, the use of biomarkers in drug discovery and development has exploded at an unprecedented rate. Recent scientific and technologic breakthroughs allow biomarkers to be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process—at a fraction […]